Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs — the most ever for the ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best future stocks to buy for the long term. On January 12, ...

Tenaya Therapeutics Inc. (NASDAQ:TNYA) is one of the overlooked growth stocks to buy. On January 8, Morgan Stanley lowered ...

Sana Biotechnology's favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a ...

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

Venture capitalists point to a surge in M&A and a glint of revival in the IPO arena as signs of better days ahead.

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

This session highlights the role of the King Abdullah International Medical Research Center (KAIMRC) as a core enabling ...

The opening session sets the context and intent for the Inaugural Summit: USA-Saudi Biotech Alliance, outlining the strategic ...

If we lose our current, increasingly endangered lead, Americans won’t merely become dependent on a communist adversary for ...